Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brexpiprazole

FDA-approved product (tablet, oral), marketed as Brexpiprazole, Rexulti.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brexpiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brexpiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brexpiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

    NCT02400346 · start 2015-03

    Registered record
    Registry ID
    NCT02400346
    Conditions
    Major Depression Disorder
    Interventions
    Adjunct brexpiprazole; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-03
    Completion
    2016-06
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression Disorder
    InterventionAdjunct brexpiprazole; ADT
    PhasePhase 3
    Registry statusCompleted

  • Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

    NCT02194933 · start 2015-02

    Registered record
    Registry ID
    NCT02194933
    Conditions
    Schizophrenia With Impulsivity
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2016-04
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia With Impulsivity
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

    NCT02212613 · start 2014-09

    Registered record
    Registry ID
    NCT02212613
    Conditions
    Major Depressive Disorder and Irritability
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2014-09
    Completion
    2015-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder and Irritability
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusWithdrawn

  • Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

    NCT02196506 · start 2014-07

    Registered record
    Registry ID
    NCT02196506
    Conditions
    Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
    Interventions
    Placebo + ADT; Brexpiprazole +ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-05
    Enrolment
    837

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders +1 more
    InterventionPlacebo + ADT; Brexpiprazole +ADT
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

    NCT02054702 · start 2014-02

    Registered record
    Registry ID
    NCT02054702
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole; Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-07
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole; Aripiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

    NCT02012218 · start 2013-11

    Registered record
    Registry ID
    NCT02012218
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    ADT; Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-10
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionADT; Brexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

    NCT02013531 · start 2013-11

    Registered record
    Registry ID
    NCT02013531
    Conditions
    Major Depressive Disorder; Anxiety
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Anxiety
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

    NCT02013609 · start 2013-11

    Registered record
    Registry ID
    NCT02013609
    Conditions
    MDD
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-10
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDD
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

    NCT02013622 · start 2013-11

    Registered record
    Registry ID
    NCT02013622
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-10
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

    NCT01942785 · start 2013-10

    Registered record
    Registry ID
    NCT01942785
    Conditions
    Major Depressive Disorder; Irritability
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10
    Completion
    Not recorded
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Irritability
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

    NCT01854944 · start 2013-09

    Registered record
    Registry ID
    NCT01854944
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole 1mg to 4mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-08
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole 1mg to 4mg
    PhasePhase 1
    Registry statusCompleted

  • Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

    NCT01942733 · start 2013-09

    Registered record
    Registry ID
    NCT01942733
    Conditions
    Sleep Disturbances
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disturbances
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

    NCT01862640 · start 2013-07-11

    Registered record
    Registry ID
    NCT01862640
    Conditions
    Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases
    Interventions
    Brexpiprazole, OPC-34712; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07-11
    Completion
    2017-03-15
    Enrolment
    433

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder +1 more
    InterventionBrexpiprazole, OPC-34712; Placebo Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole in Patients With Schizophrenia

    NCT01810783 · start 2013-07

    Registered record
    Registry ID
    NCT01810783
    Conditions
    Schizophrenia
    Interventions
    Brexpiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07
    Completion
    2015-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBrexpiprazole
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

    NCT01838681 · start 2013-06

    Registered record
    Registry ID
    NCT01838681
    Conditions
    Major Depressive Disorder
    Interventions
    Placebo; Brexpiprazole; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-06
    Enrolment
    1,986

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPlacebo; Brexpiprazole; ADT
    PhasePhase 3
    Registry statusCompleted